Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder

Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached.

from Reuters: Health News https://reut.rs/2Hao93E
via IFTTT